Biotech Startup Mosanna Secures €70.1Million In Series A Round

The round was led by Pivotal bioVenture Partners and EQT Life Sciences, with support from Forbion, Broadview Ventures, and Norwest as co-lead investors.

Returning investors in the round included Forty51 Ventures (a founding investor), Supermoon Capital, and High-Tech Gründerfonds (HTGF).

Read Also - Deep Tech Startup HoloMem Awarded Innovate UK Smart Grant For HoloDrive

HTGF is a leading early-stage investor based in Bonn, Germany. It supports startups in areas like Deep Tech, Climate Tech, Life Sciences, and more—mainly at the pre-seed and seed stages, but also in later rounds.

Since 2005, HTGF has backed over 770 startups, achieved nearly 200 exits, and now manages more than €2 billion across its funds.

Dr. Laura Pedroza, Senior Investment Manager at HTGF, says, “This is a great achievement by the Mosanna team! As investors since the seed round and in this Series A, we are excited to see MOS118 advance into the clinical stage. The simple mode of application via a nasal spray has the potential to drastically improve the life of patients suffering from sleep apnea.”

The new funding will help move MOS118 into Phase 2 trials and also support the growth of Mosanna’s product pipeline.

Along with the new funding, Mosanna has appointed biotech veteran Dr. David Weber as its new President and CEO. With over 30 years of experience in drug development, fundraising, and corporate strategy, Dr. Weber has led teams in both public and private life sciences companies. He has also joined Mosanna’s Board of Directors.

“Mosanna is taking a truly transformational approach to sleep apnea treatment – offering a non-invasive, non-mechanical solution designed to seamlessly fit into daily life,” says Dr. Weber.

“No one has sleep apnea while awake because our bodies instinctively keep the airway open. Mosanna simply helps to restore this natural reflex during sleep, delivering a nasal spray alternative to invasive mechanical workarounds. With this funding, we’re accelerating development to bring this groundbreaking treatment to patients who desperately need better options.”

In the recent funding round, Dr. Stefano Begolo and Lee joined the Board of Directors, alongside Dmitrij Hristodorov, Ph.D., General Partner at Forbion, Hewmun Lau, M.B.A., Principal at Broadview Ventures, and Tiba Aynechi, Ph.D., General Partner at Norwest.

They join existing board members Sascha Oliver Bucher, M.B.A., CEFA, co-founder and Partner at Forty51 Ventures, and Ben Machielse, a veteran biotech CEO who also serves as board chair.

Obstructive Sleep Apnea (OSA) is the most common sleep disorder, affecting nearly 1 billion people worldwide.

If not treated, it can lead to serious health issues such as high blood pressure, heart disease, stroke, depression, and extreme daytime tiredness, which can cause accidents at work or while driving.

Although OSA is widespread, most treatments involve machines that many people find uncomfortable and hard to use.

Mosanna’s lead candidate, MOS118, is designed to restore the body’s natural airway control during sleep by targeting the upper airway muscles responsible for maintaining an open airway. Currently, MOS118 is being evaluated in a Phase 1 clinical trial. Headquartered in Redwood City, California, Mosanna also has an office in Basel, Switzerland, supporting its global research and development efforts.

About Mosanna Therapeutics

Founded in 2022, Mosanna Therapeutics is a clinical-stage biotech company dedicated to developing innovative treatments for obstructive sleep apnea (OSA). The company is pioneering a novel pharmaceutical approach using an easily administered nasal spray as an alternative to traditional mechanical therapies.